Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines

Nektarios Barabutis, Agnieszka Siejka, Andrew V Schally

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The neuropeptide growth hormone-releasing hormone (GHRH) is secreted by the hypothalamus and upon the binding to the receptors for GHRH on the pituitary gland regulates the release of growth hormone. Substantial evidence indicate that GHRH, in addition to its physiological role as a hypophysiotrophic hormone, acts as a growth factor in diverse tissues and various tumors. In this study we evaluated the expression of GHRH and its receptors in a variety of cancer and non-cancerous cell lines and studied the effect of GHRH antagonists and agonists on the proliferative cell nuclear antigen, cyclin D3, tumor suppressor protein p53 and carboxyl-terminal-binding protein (CtBP1). Our findings show that GHRH agonist JI-38 downregulates wt-p53 and upregulates the expression of PCNA. GHRH also upregulates CtBP1 protein expression and its antagonists downregulate it in LNCaP prostate cancer cells. Furthermore, GHRH and its agonist JI-38 upregulates the expression of the proliferative markers cyclin D3 and PCNA in A549 non-small cell lung carcinoma and GHRH antagonist MZ-5-156 downregulates it. Our results support previous findings on the mitogenic role of GHRH in cancers and underline the importance of GHRH antagonists as anticancer agents.

Original languageEnglish
Pages (from-to)1285-1289
Number of pages5
JournalInternational Journal of Oncology
Volume36
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Growth Hormone-Releasing Hormone
Cell Line
Hormone Antagonists
Neoplasms
Cyclin D3
Up-Regulation
Down-Regulation
Proliferating Cell Nuclear Antigen
Tumor Suppressor Protein p53
Nuclear Antigens
Pituitary Gland
Neuropeptides
Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Growth Hormone
Hypothalamus
Prostatic Neoplasms
Intercellular Signaling Peptides and Proteins
Carrier Proteins
Hormones

Keywords

  • Growth factor
  • Growth hormone-releasing hormone
  • Growth hormone-releasing hormone receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines. / Barabutis, Nektarios; Siejka, Agnieszka; Schally, Andrew V.

In: International Journal of Oncology, Vol. 36, No. 5, 01.05.2010, p. 1285-1289.

Research output: Contribution to journalArticle

@article{1b9bae78aaf44f999b8da909ba28dd03,
title = "Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines",
abstract = "The neuropeptide growth hormone-releasing hormone (GHRH) is secreted by the hypothalamus and upon the binding to the receptors for GHRH on the pituitary gland regulates the release of growth hormone. Substantial evidence indicate that GHRH, in addition to its physiological role as a hypophysiotrophic hormone, acts as a growth factor in diverse tissues and various tumors. In this study we evaluated the expression of GHRH and its receptors in a variety of cancer and non-cancerous cell lines and studied the effect of GHRH antagonists and agonists on the proliferative cell nuclear antigen, cyclin D3, tumor suppressor protein p53 and carboxyl-terminal-binding protein (CtBP1). Our findings show that GHRH agonist JI-38 downregulates wt-p53 and upregulates the expression of PCNA. GHRH also upregulates CtBP1 protein expression and its antagonists downregulate it in LNCaP prostate cancer cells. Furthermore, GHRH and its agonist JI-38 upregulates the expression of the proliferative markers cyclin D3 and PCNA in A549 non-small cell lung carcinoma and GHRH antagonist MZ-5-156 downregulates it. Our results support previous findings on the mitogenic role of GHRH in cancers and underline the importance of GHRH antagonists as anticancer agents.",
keywords = "Growth factor, Growth hormone-releasing hormone, Growth hormone-releasing hormone receptor",
author = "Nektarios Barabutis and Agnieszka Siejka and Schally, {Andrew V}",
year = "2010",
month = "5",
day = "1",
doi = "10.3892/ijo-00000613",
language = "English",
volume = "36",
pages = "1285--1289",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines

AU - Barabutis, Nektarios

AU - Siejka, Agnieszka

AU - Schally, Andrew V

PY - 2010/5/1

Y1 - 2010/5/1

N2 - The neuropeptide growth hormone-releasing hormone (GHRH) is secreted by the hypothalamus and upon the binding to the receptors for GHRH on the pituitary gland regulates the release of growth hormone. Substantial evidence indicate that GHRH, in addition to its physiological role as a hypophysiotrophic hormone, acts as a growth factor in diverse tissues and various tumors. In this study we evaluated the expression of GHRH and its receptors in a variety of cancer and non-cancerous cell lines and studied the effect of GHRH antagonists and agonists on the proliferative cell nuclear antigen, cyclin D3, tumor suppressor protein p53 and carboxyl-terminal-binding protein (CtBP1). Our findings show that GHRH agonist JI-38 downregulates wt-p53 and upregulates the expression of PCNA. GHRH also upregulates CtBP1 protein expression and its antagonists downregulate it in LNCaP prostate cancer cells. Furthermore, GHRH and its agonist JI-38 upregulates the expression of the proliferative markers cyclin D3 and PCNA in A549 non-small cell lung carcinoma and GHRH antagonist MZ-5-156 downregulates it. Our results support previous findings on the mitogenic role of GHRH in cancers and underline the importance of GHRH antagonists as anticancer agents.

AB - The neuropeptide growth hormone-releasing hormone (GHRH) is secreted by the hypothalamus and upon the binding to the receptors for GHRH on the pituitary gland regulates the release of growth hormone. Substantial evidence indicate that GHRH, in addition to its physiological role as a hypophysiotrophic hormone, acts as a growth factor in diverse tissues and various tumors. In this study we evaluated the expression of GHRH and its receptors in a variety of cancer and non-cancerous cell lines and studied the effect of GHRH antagonists and agonists on the proliferative cell nuclear antigen, cyclin D3, tumor suppressor protein p53 and carboxyl-terminal-binding protein (CtBP1). Our findings show that GHRH agonist JI-38 downregulates wt-p53 and upregulates the expression of PCNA. GHRH also upregulates CtBP1 protein expression and its antagonists downregulate it in LNCaP prostate cancer cells. Furthermore, GHRH and its agonist JI-38 upregulates the expression of the proliferative markers cyclin D3 and PCNA in A549 non-small cell lung carcinoma and GHRH antagonist MZ-5-156 downregulates it. Our results support previous findings on the mitogenic role of GHRH in cancers and underline the importance of GHRH antagonists as anticancer agents.

KW - Growth factor

KW - Growth hormone-releasing hormone

KW - Growth hormone-releasing hormone receptor

UR - http://www.scopus.com/inward/record.url?scp=77950419066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950419066&partnerID=8YFLogxK

U2 - 10.3892/ijo-00000613

DO - 10.3892/ijo-00000613

M3 - Article

C2 - 20372804

AN - SCOPUS:77950419066

VL - 36

SP - 1285

EP - 1289

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -